{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-258963","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.293917+00:00","generated_at":"2026-06-09T20:59:00.520096+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026","bullets":["Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.","Prioritizes BEAM-101, ESCAPE, and in vivo sickle cell programs; BEAM-302 for AATD.","Explores partnerships for BEAM-201 and other CAR-T programs; pauses hepatitis B program.","Cash, equivalents, and securities of $1.1B (June 30, 2023) expected to fund operations into 2026.","Strategic restructuring aims to streamline operations and focus on near-term value drivers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-258963","json":"https://secwatch.observer/filing/0001193125-23-258963.json","markdown":"https://secwatch.observer/filing/0001193125-23-258963.md","text":"https://secwatch.observer/filing/0001193125-23-258963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/0001193125-23-258963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/d517250d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:59:00.520096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b637f1f7653942eaaa095caf5eefe1857db4985a","claim":"Beam Therapeutics Inc. announced a restructuring with charges of approximately $6.6 million affecting not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics (approximately 100 positions, or about 20% of its workforce).","evidence_excerpt":"the Company expects to reduce its employee headcount by approximately 100 positions, or about 20% of its workforce. The Company expects to incur one-time costs of approximately $6.6 million in the fourth quarter of 2023 in connection with the workforce reduction. These costs consist primarily of cash expenditures related to severance payments. The Company estimates","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/0001193125-23-258963-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.6 million"},{"label":"Affected area","value":"not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics"},{"label":"Headcount","value":"approximately 100 positions, or about 20% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}